Sign In
Buy CLOV
$4.27
-0.0600 (-1.39%)
At Close: Aug 04, 2026
Here's Why You Should Add CLOV Stock to Your Portfolio Now
10:50am, Friday, 29'th Aug 2025
Clover's strong membership growth, rising revenues, and first-half EBITDA profitability highlight its tech-driven Medicare Advantage edge.
Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now
10:56am, Thursday, 21'st Aug 2025
Clover Health Investments (CLOV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agre
Clover Health: Short-Term Pain Hides Its Long-Term Profitability Potential
10:29am, Monday, 11'th Aug 2025
While Clover Health's Q2 earnings showed continued member and revenue growth, it dropped 30% since then due to higher medical costs that impacted all MA plan providers. Clover Health still maintains i
CLOV Q2 Earnings In Line, Stock Falls on Raised Insurance BER View
11:41am, Wednesday, 06'th Aug 2025
Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.
Clover Health (CLOV) Q2 Sales Up 34%
09:43pm, Tuesday, 05'th Aug 2025
Clover Health (CLOV) Q2 Sales Up 34%
Clover Health Investments, Corp. (CLOV) Q2 2025 Earnings Call Transcript
08:39pm, Tuesday, 05'th Aug 2025
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Andrew Toy - Co-Founder, CEO & Director Peter J. Kuipers - Chief Financi
Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates
07:06pm, Tuesday, 05'th Aug 2025
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.01 per share a year ago.
Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth
04:05pm, Tuesday, 05'th Aug 2025
Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-year Second quarter 2025 Total revenues of $478 million, up 34% year-over-year Second quarter 2025 profitability metrics
New whitepaper shows that a relationship with a primary care physician (“PCP”) who uses Counterpart Assistant is correlated with more frequent Chronic Obstructive Pulmonary Disease (“COPD”) di
Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?
09:50am, Friday, 01'st Aug 2025
CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.
WILMINGTON, Del., July 31, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a physician enablement company bringing access to great healthcare to everyon
Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution
04:30pm, Tuesday, 29'th Jul 2025
WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover
OSCR vs. CLOV: Which Stock Is A Better Buy Now?
06:08am, Monday, 28'th Jul 2025
In this piece, we'll check in on two mid-cap health insurance plays that are leveraging their tech-savvy and digital strengths to grab a bigger slice of the health insurance industry.
TotalEnergies - Angola: Start-up of BEGONIA and CLOV Phase 3 Offshore Projects
09:42am, Wednesday, 23'rd Jul 2025
PARIS--(BUSINESS WIRE)--TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) announces the start of production from the BEGONIA and CLOV Phase 3 offshore projects, leveraging ullage in the PAZFLOR and CLOV
Clover Health to Participate in Upcoming Canaccord Genuity 45th Annual Growth Conference
04:05pm, Monday, 21'st Jul 2025
WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial O
